RNAi therapies: Drugging the undruggable

Sherry Y. Wu; Gabriel Lopez-Berestein; George A. Calin; Anil K. Sood

doi:10.1126/scitranslmed.3008362

RNAi therapies: Drugging the undruggable

Sherry Y. Wu, Gabriel Lopez-Berestein, George A. Calin, Anil K. Sood

Research output: Contribution to journal › Review article › peer-review

219 Scopus citations

Abstract

RNA interference (RNAi) therapy is a rapidly emerging platform for personalized cancer treatment. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation. Here, we discuss these advances and present strategies for making RNAi-based therapy a viable part of cancer management.

Original language	English (US)
Article number	240ps7
Journal	Science translational medicine
Volume	6
Issue number	240
DOIs	https://doi.org/10.1126/scitranslmed.3008362
State	Published - Jun 11 2014

ASJC Scopus subject areas

General Medicine

Access to Document

10.1126/scitranslmed.3008362

Cite this

@article{2a45ea8c81e24bf2ac597621a7600c0f,

title = "RNAi therapies: Drugging the undruggable",

abstract = "RNA interference (RNAi) therapy is a rapidly emerging platform for personalized cancer treatment. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation. Here, we discuss these advances and present strategies for making RNAi-based therapy a viable part of cancer management.",

author = "Wu, {Sherry Y.} and Gabriel Lopez-Berestein and Calin, {George A.} and Sood, {Anil K.}",

year = "2014",

month = jun,

day = "11",

doi = "10.1126/scitranslmed.3008362",

language = "English (US)",

volume = "6",

journal = "Science translational medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "240",

}

TY - JOUR

T1 - RNAi therapies

T2 - Drugging the undruggable

AU - Wu, Sherry Y.

AU - Lopez-Berestein, Gabriel

AU - Calin, George A.

AU - Sood, Anil K.

PY - 2014/6/11

Y1 - 2014/6/11

N2 - RNA interference (RNAi) therapy is a rapidly emerging platform for personalized cancer treatment. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation. Here, we discuss these advances and present strategies for making RNAi-based therapy a viable part of cancer management.

AB - RNA interference (RNAi) therapy is a rapidly emerging platform for personalized cancer treatment. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation. Here, we discuss these advances and present strategies for making RNAi-based therapy a viable part of cancer management.

UR - http://www.scopus.com/inward/record.url?scp=84903133224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903133224&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3008362

DO - 10.1126/scitranslmed.3008362

M3 - Review article

C2 - 24920658

AN - SCOPUS:84903133224

SN - 1946-6234

VL - 6

JO - Science translational medicine

JF - Science translational medicine

IS - 240

M1 - 240ps7

ER -

RNAi therapies: Drugging the undruggable

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this